Alzamend Neuro™, Inc.

Alzamend Neuro™, Inc. (Closed)

Alzamend Neuro™ is Dedicated to Finding the Treatment and Cure for Alzheimer's Disease. Alzamend is raising up to $50 million in this Mini-IPO. Help fight Alzheimer's, Buy your shares now! For more information or assistance with this Offering, please use our Live Chat or call (888) 745-2574.


Overview of a Reg A+: Invest $100 or more in this Mini-IPO. Alzamend Neuro™ is raising up to $50 million

In the past, only wealthy investors, venture capitalists, and private equity firms have had the opportunity to invest via special securities in private to public transactions. That has changed as of June 2015. In light of this change, we are now allowed to invite existing investors, friends, associates and the general public to participate in the growth of Alzamend Neuro, Inc.

You can help support the Alzamend Neuro mission and participate in the Company as an equity shareholder, too. For as little as $100.00, you can participate as an owner. Alzamend Neuro currently has been qualified by the SEC to raise $50,000,000 dollars using the Reg A+ exemption. This allows the Company to accept investment from all types of investors including accredited, non-accredited and institutional.

By selecting the Invest Now button above, you can review the Offering Statement and Offering Circular and is where you can get more information on how to invest.

Our Story

“I remember, like it was just yesterday, my grandmother no longer recognized me and worse yet, feared me as if I was a stranger. That was my first true experience of what Alzheimer’s is”. Later I would learn about and experience more than 6 direct family members systematically consumed by the disease, and watched helplessly.” – Chairman Milton “Todd” Ault III

Through his personal experience and diligent study of the status of treatments, and the landscape of medical technology, Mr. Ault, chose the USF Health/Byrd Alzheimer's Institute and their intellectual property portfolio and formed Alzamend Neuro as his starting point to make a difference. With twenty-five years of experience on Wall Street at buying and selling companies as an activist, his relentless passion for business and technology has culminated in a commitment to depart from the traditional while forging ahead with a disruptive path to financing the commercialization  and the discovery of future solutions.

Mr. Ault was quick to recognize the opportunity to make a difference in routine medical procedures that at times resulted in fatal consequences. He founded and launched Patient Safety Technologies Inc., believing in the impact of bar-coded sponge technology, long before anyone else would support it. It has now become the standard of care in operating rooms around the world, saving countless lives and subsequent lawsuits annually.

Providing a team of Operational and Financial executives with proven track records, Mr. Ault has assembled an all-star cast to move this vision forward, without burdening the company with excessive overhead.





Philip E. Mansour President and Chief Executive Officer
Mr. Mansour has been actively involved with disruptive technology as an inventor, manager, executive and coach for more than 3 decades. During that period he has led innovation and inspired collaboration among facilities in seven states and four contents. He is a master of operations, organizational change management and integrations having experienced all sides and process of a merger and acquisition transaction through more than a dozen transactions. His executive positions include CEO, CTO, President, Senior VP of Research and Development, Executive VP of corporate development, and VP of Strategic Initiatives. He served as a Board Member and Treasure of Concievex, Inc., a company with the first FDA cleared medical device to help couples with specific fertility challenges. He also is currently on the Board of Directors for Avalanche International Corp. Through his consulting organization, PMC Solutions, he has facilitated organizations, entrepreneurs, and disruptive technologies and business models in the sectors of, Bio-Technology, Consumer Electronics, Computer Science, Energy, Health Sciences, Hospitality, and Publishing, Mr. Mansour has been retained to establish the Company, its Board of Directors, the Scientific Advisory board, hire and contract with all appropriate FDA consulting firms, as well as establish and negotiate all relationships with the scientific and academic communities. His substantial entrepreneurial and corporate experience will benefit the Company, including, but not limited to, establishing its infrastructure, attracting and hiring appropriate leadership, and guiding its progression through its projected growth.

William B. Horne Chief Financial Officer
Mr. Horne served as the Chief Financial Officer of Targeted Medical Pharma, Inc. (OTCBB: TRGM) since August 2013. Mr. Horne previously held the position of Chief Financial Officer in various companies in the healthcare and high-tech field, including OptimisCorp, from January 2008 to May 2013, a privately held, diversified healthcare technology company located in Los Angeles, California. Mr. Horne served as the Chief Financial Officer of Patient Safety Technologies, Inc. (OTCBB: PSTX), a medical device company located in Irvine, California, from June 2005 to October 2008 and as the interim Chief Executive Officer from January 2007 to April 2008. In his dual role at Patient Safety Technologies, Mr. Horne was directly responsible for structuring the divestiture of non-core assets, capital financings and debt restructuring. Mr. Horne held the position of Managing Member & Chief Financial Officer of Alaska Wireless Communications, LLC, a privately held, advanced cellular communications company, from its inception in May 2002 until November 2007. Mr. Horne was responsible for negotiating the sale of Alaska Wireless to General Communication Inc. (NASDAQ: GNCMA). From November 1996 to December 2001, Mr. Horne held the position of Chief Financial Officer of The Phoenix Partners, a venture capital limited partnership located in Seattle, Washington. Mr. Horne has also held supervisory positions at Price Waterhouse, LLP and has a Bachelor of Arts Magna Cum Laude in Accounting from Seattle University

Chuanhai Cao Professor & Research Team Leader (USF Health/Byrd Alzheimer's Institute)

Dr. Cao is a Professor at the University of South Florida College of Pharmacy. He works out his lab on the 4th Floor of the USF Health/Byrd Alzheimer’s Research Institute located on the USF Main Campus. His research interests are focused on the discovery of therapeutics and vaccinations to neurological diseases, such as Alzheimer’s, Parkinsons, Multiple Sclerosis, and ALS among many others.

Read More About Dr. Cao



Milton "Todd" Ault III Chairman of the Board and Founder

Mr. Ault is a seasoned business professional and entrepreneur that has spent more than twenty-seven years identifying value in various financial markets including equities, fixed income, commodities, and real estate. Mr. Ault’s most recent efforts have been as a consultant to a few publicly traded and privately-held companies, where he has provided each of them the benefit of his diversified experience, ranging from development stage to seasoned businesses. He was the President, Chief Executive Officer, Director and Chairman of the Board of Zealous, Inc. from August 2007 until June 4, 2010 and again from February 2011 through May 1, 2011. Mr. Ault was a registered representative at Strome Securities, LP, from July 1998 until December 2005, where he was involved in portfolio management and worked on several activism campaigns including Taco Cabana, Jack In The Box (formerly Foodmaker), and 21st Century Holdings Co. Mr. Ault was elected to the board of directors of Patient Safety Technologies, Inc. (OTCBB:PSTX, OTCQB:PSTX) (“PST”) in July 2004, and became its Chairman and Chief Executive Officer in October 2004 serving until January 2006, and again from July 2006 to January 2007. Stryker Corporation (NYSE:SYK) acquired PST at the beginning of 2014 in a deal valued at approximately one hundred twenty million dollars ($120,000,000). PST’s wholly-owned operating subsidiary, SurgiCount Medical, Inc., is the company that developed the Safety-Sponge® System; a bar coding technology for inventory control that aims to detect and prevent the incidence of foreign objects left in the body after surgery.

Alzamend Neuro™, Inc.

Alzamend Neuro™ is a development stage biotechnology company currently working to move a patented mutant peptide for use as an immunotherapeutic treatment and vaccine out of the research and pre-clinical stage at the University of South Florida Health/Byrd Institute and into a path toward commercialization.

Alzamend Neuro™ has been qualified by the SEC to raise $50 Million dollars under the new Regulation A+ which was signed into law by President Obama as part of the Jobs Act of 2012. Alzamend Neuro is the first BIo-Tech company to receive this qualification.

Through the licensing of promising intellectual property from internationally recognized organizations, moving it forward toward commercialization and the support of ongoing research Alzamend Neuro, has and will continue to strive help move the battle against Alzheimer's forward.



Certain statements within this website including, but not limited to, statements related to anticipated commencement of commercial production, targeted pricing and performance goals, and statements that otherwise relate to future periods are forward-looking statements. These statements involve risks and uncertainties, which are described in more detail in the Company’s Offering Statement on Form 1-A filed with the Securities and Exchange Commission, which identifies important risk factors that could cause actual results to differ from those contained in the forward-looking statements. Forward-looking statements may also be included in future periodic reports filed by Alzamend Neuro. Forward-looking statements are made and based on information available to the Company on the date of this website. Alzamend Neuro assumes no obligation to update the information within this website.

An offering statement regarding this offering has been filed with the sec. The SEC has qualified that offering statement, which only means that the company may make sales of the securities described by the offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. You may obtain a copy of the offering circular that is part of that offering statement from

• Alzamend Neuro is a registered mark of Alzamend Neuro™, Inc. • 2016-2017 by Alzamend Neuro, Inc. All rights reserved.

Alzamend Neuro™ Regulation A+ Tier II Capital Raise

Committed to the Prevention, Treatment & Cure of Alzheimer’s

Alzamend Neuro™ is currently working to move a patented mutant peptide for use as an immunotherapeutic treatment and vaccine out of the research and pre-clinical stage at the University of South Florida Health/Byrd Institute and into a path toward commercialization.

Simultaneously, Alzamend Neuro™ going forward through this Regulation A+ Tier II Offering intends to commit a significant portion of the funds raised directly to fund ongoing research projects with National Partners like the University of South Florida Health/Byrd Institute to secure future intellectual property license rights for commercialization.

“Alzamend Neuro™ is committed to supporting the full product development life cycle of treatment and cures for Alzhiemer’s believing that strong support of research is the foundation for true innovation. Providing current hope though the commercialization of existing patented intellectual property and know how while simultaneously funding future hope through advance research,” said Philip Mansour, President and Chief Executive Officer of Alzamend Neuro™.

What is Alzheimer's Disease? What you should know!

Alzheimer's Disease by the Numbers!